Filing Details
- Accession Number:
- 0000880771-17-000020
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-02-27 17:55:48
- Reporting Period:
- 2017-02-24
- Filing Date:
- 2017-02-27
- Accepted Time:
- 2017-02-27 17:55:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 880771 | Sciclone Pharmaceuticals Inc | SCLN | Pharmaceutical Preparations (2834) | 943116852 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1363213 | Friedhelm Blobel | 950 Tower Lane, Suite 900 Foster City CA 94404 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-02-24 | 823 | $1.08 | 87,607 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-24 | 823 | $9.71 | 86,784 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-qualified Stock Option (right to buy) | Disposition | 2017-02-24 | 823 | $0.00 | 823 | $1.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 20,400 | 2019-03-06 | No | 4 | M | Direct |
Footnotes
- The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- Granted under the Issuer's 2005 Equity Incentive Plan.
- 25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
Billionaire Hedge Funds
